Knodell necroinflammatory score

Related by string. * : Jane Knodell . Knodell . James Knodell / : / scor ed . www.score . SCORES . Scores . SCORE . Score . scores : TIME SCORE MAR VISITORS . SCORE Desert Series . SCORE Trophy Truck . Herb Score . Industry Risk Score . Best Original Score . Tecate SCORE Baja . SCORE Counselors . Oncotype DX Recurrence Score . SAT scores . Box Score . score . Propensity score weighting . MCAS scores * *

Related by context. Frequent words. (Click for all words.) 60 symptom severity 60 DAS# [002] 58 proteinuria 58 IPSS 58 HbA1c levels 57 leukopenia 57 plus methotrexate 57 serum phosphorus 57 glomerular filtration rate 57 inflammatory lesions 57 creatinine clearance 57 A1C levels 57 annualized relapse 56 placebo p 56 ADHD RS 56 mg BID 56 placebo p = 55 infarct size 55 LVEF 55 PANSS 54 severe renal impairment 54 hypomagnesemia 54 fasting plasma glucose 54 peginterferon alfa 2a 54 febrile neutropenia 54 target vessel revascularization 54 albuminuria 54 P = .# 53 log# 53 laboratory abnormalities 53 HCV RNA 53 hypokalemia 53 composite endpoint 53 nmol L 53 sustained virologic response 52 Cmax 52 FEV1 52 cytogenetic response 52 mg kg dose 52 IU mL 52 CD4 + cell 52 platelet aggregation 52 mcg kg 52 microalbuminuria 52 fasting blood glucose 52 serum concentrations 51 serum creatinine 51 statistically significant p 51 eGFR 51 preoperatively 51 vertebral fracture 51 orthostatic hypotension 51 copies mL 51 Secondary endpoints include 51 renal dysfunction 51 confidence interval #.#-#.# 51 mmHg 51 dyspnea 51 plus ribavirin 50 diastolic pressure 50 fasting insulin 50 HbA1c 50 % CI #.#-#.# [006] 50 hypercalcemia 50 EDSS 50 alkaline phosphatase 50 ACR# [002] 50 discontinuations due 50 nonresponders 50 pg mL 50 nM 50 g dL 50 mg dL 50 confidence interval CI 50 mg d 49 hemoglobin A1C 49 platelet counts 49 NYHA class 49 primary efficacy endpoint 49 median PFS 49 49 dose cohorts 49 virologic failure 49 plasma concentrations 49 titers 49 adenoma 49 hyperkalemia 49 mitral regurgitation 49 thromboembolic events 49 cardiovascular mortality 49 hyperuricemia 49 ejection fraction 49 placebo 49 secondary endpoint 49 peginterferon alfa 2b 49 prespecified 49 ng mL 48 hepatotoxicity 48 mm Hg 48 6R BH4 48 adalimumab

Back to home page